Research ArticleOriginal Article
Open Access

The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma

Hyun Hwang and Nam Kwon Lee
Saudi Medical Journal August 2021, 42 (8) 832-837; DOI: https://doi.org/10.15537/smj.2021.42.8.20210127

References

  1. 1.↵
    1. Cooper DS,
    2. Doherty GM,
    3. Haugen BR,
    4. Kloos RT,
    5. Lee SL,
    6. Mandel SJ, et al.
    Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Lee N,
    2. Tuttle M.
    The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer 2006; 13: 971–977.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2019). [Updated 2019. Assessed 2019 September 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
  4. 4.↵
    1. Lee NK,
    2. Kim CY,
    3. Baek SK,
    4. Jung KY.
    The role of adjuvant radiation therapy for locoregionally advanced papillary thyroid carcinoma. Oncology 2016; 90: 209–214.
    OpenUrl
  5. 5.
    1. Kim TH,
    2. Yang DS,
    3. Jung KY,
    4. Kim CY,
    5. Choi MS.
    Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1006–1012.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    1. Chow SM,
    2. Yau S,
    3. Kwan CK,
    4. Poon PC,
    5. Law SC.
    Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 2006; 13: 1159–1172.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Keum KC,
    2. Suh YG,
    3. Koom WS,
    4. Cho JH,
    5. Shim SJ,
    6. Lee CG, et al.
    The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys 2006; 65: 474–480.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    1. Meadows KM,
    2. Amdur RJ,
    3. Morris CG,
    4. Villaret DB,
    5. Mazzaferri EL,
    6. Mendenhall WM.
    External beam radiotherapy for differentiated thyroid cancer. Am J Otolaryngol 2006; 27: 24–28.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Kim YS,
    2. Choi JH,
    3. Kim KS,
    4. Lim GC,
    5. Kim JH,
    6. Kang JW, et al.
    The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea. Radiat Oncol J 2017; 35: 112–120.
    OpenUrl
  10. 10.↵
    1. Terezakis SA,
    2. Lee KS,
    3. Ghossein RA,
    4. Rivera M,
    5. Tuttle RM,
    6. Wolden SL, et al.
    Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: memorial sloan-kettering cancer center experience. Int J Radiat Oncol Biol Phys 2009; 73: 795–801.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Baek SK,
    2. Jung KY,
    3. Kang SM,
    4. Kwon SY,
    5. Woo JS,
    6. Cho SH, et al.
    Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 2010; 20: 147–152.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Cox JD,
    2. Stetz J,
    3. Pajak TF.
    Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–1346.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Fussey JM,
    2. Crunkhorn R,
    3. Tedla M,
    4. Weickert MO,
    5. Mehanna H.
    External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck 2016; 38: E2297–E2305.
    OpenUrl
  14. 14.↵
    1. Jacomina LE,
    2. Jacinto JKM,
    3. Co LBA,
    4. Yu KKL,
    5. Agas RAF,
    6. Co JL, et al.
    The role of postoperative external beam radiotherapy for differentiated thyroid carcinoma: a systematic review and meta-analysis. Head Neck 2020; 42: 2181–2193.
    OpenUrl
  15. 15.↵
    1. Gupta T,
    2. Agarwal J,
    3. Jain S,
    4. Phurailatpam R,
    5. Kannan S,
    6. Ghosh-Laskar S, et al.
    Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 2012; 104: 343–348.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Cozzi L,
    2. Fogliata A,
    3. Bolsi A,
    4. Nicolini G,
    5. Bernier J.
    Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004; 58: 617–624.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Palme CE,
    2. Waseem Z,
    3. Raza SN,
    4. Eski S,
    5. Walfish P,
    6. Freeman JL.
    Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 819–824.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Shokoohi A,
    2. Berthelet E,
    3. Gill S,
    4. Prisman E,
    5. Sexsmith G,
    6. Tran E, et al.
    Treatment for recurrent differentiated thyroid cancer: a Canadian population based experience. Cureus 2020; 12: e7122.
    OpenUrl
  19. 19.↵
    1. Dong W,
    2. Horiuchi K,
    3. Tokumitsu H,
    4. Sakamoto A,
    5. Noguchi E,
    6. Ueda Y, et al.
    Time-varying pattern of mortality and recurrence from papillary thyroid cancer: lessons from a long-term follow-up. Thyroid 2019; 29: 802–808.
    OpenUrl
  20. 20.↵
    1. Grogan RH,
    2. Kaplan SP,
    3. Cao H,
    4. Weiss RE,
    5. Degroot LJ,
    6. Simon CA, et al.
    A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 2013; 154: 1436–1446.
    OpenUrlPubMed
  21. 21.↵
    1. Guo K,
    2. Wang Z.
    Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol 2014; 7: 5393–5403.
    OpenUrl
  22. 22.↵
    1. Zahedi A,
    2. Bondaz L,
    3. Rajaraman M,
    4. Leslie WD,
    5. Jefford C,
    6. Young JE, et al.
    Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 2020; 30: 871–877.
    OpenUrl
  23. 23.↵
    1. Toniato A,
    2. Boschin I,
    3. Casara D,
    4. Mazzarotto R,
    5. Rubello D,
    6. Pelizzo M.
    Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol 2008; 15: 1518–1522.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Hwangbo Y,
    2. Kim JM,
    3. Park YJ,
    4. Lee EK,
    5. Lee YJ,
    6. Park DJ, et al.
    Long-term recurrence of small papillary thyroid cancer and its risk factors in a Korean multicenter study. J Clin Endocrinol Metab 2017; 102: 625–633.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords